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Abstract
Background: Pitt-Hopkins syndrome (PTHS; MIM# 610954) is a genetically determined entity mainly caused by
mutations in TransCription Factor 4 (TCF4). We have developed a new way to collect information on (ultra-)rare
disorders through a web-based database which we call ‘waihonapedia’ (waihona [meaning treasure in Hawaiian]
encyclopaedia).
Methods: We have built a waihonapedia system in a collaboration between physicians, social scientists, and parent
support groups. The system consists of an initial extensive questionnaire for background cross-sectional data,
and subsequent follow-up using small questionnaires, with a particular focus on behavioural aspects. The system was
built to be used through the internet, ensuring a secure environment, respecting privacy for participants, and acting
automated to allow for low costs and limiting human mistakes in data handling. Recruitment of participants is through
the patient support groups. In addition, as a sub-study, we used the data from the waihonapedia system to compare
the two proposed diagnostic classification systems for PTHS.
Results: We present here the results of the initial, cross-sectional questionnaire in which early development, physical
health, cognition and behaviour are interrogated, and to which modules specific for PTHS were added on epilepsy
and breathing patterns. We describe 101 individuals with a molecularly confirmed diagnosis of PTHS.
Comparison of the two classification systems aimed at helping the clinical diagnosis was performed in 47 of the
present PTHS individuals, with disappointing results for both. Internationally accepted clinical diagnostic criteria are
needed.
Conclusion: The present cross-sectional data on the natural history of PTHS have yielded useful information which will
further increase when follow-up data will be added. No doubt this will improve both care and research.
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Background
Pitt-Hopkins syndrome (PTHS; MIM# 610954) is an in-
frequently reported entity, first described in 1978 in two
unrelated individuals [1], and characterized by an in-
tellectual disability, abnormal breathing patterns, and
a specific facial gestalt, including deep-set eyes, a
broad nasal base and a wide mouth with a tented
upper lip [2–6]. Reliable figures for prevalence are
not available. The gene TransCription Factor 4 (TCF4;
MIM# 602272), located at 18q21 and encoding a class
I basic helix-loop-helix transcription factor (bHLH),
has been found to be the main disease causing gene
[7–9]. A large number of different TCF4 mutations
and deletions have been described, with approximately
40 % point mutations, 30 % small deletions/insertions,
and 30 % deletions [3]. In early human development
TCF4 is highly expressed in the central and enteric
nervous system, the sclerotome, the peribronchial and
kidney mesenchyme, and the genital bud [10]. Tissue
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specificity of TCF4 expression and its interaction with
other bHLH proteins are likely to explain the intellec-
tual and developmental disabilities, unusual breathing
patterns and epilepsy in PTHS individuals, as well as
MRI brain abnormalities such as underdevelopment
of the corpus callosum and hippocampus, posterior
fossa abnormalities and ventricular dilatation [3, 4,
10, 11]. It has been suggested that missense muta-
tions are associated with higher seizure activity [5],
but others did not detect a genotype-phenotype correl-
ation [3]. Additional manifestations of PTHS are ophthal-
mologic signs (strabismus, myopia, astigmatism), epilepsy,
constipation, gastro-oesophageal reflux, scoliosis, ataxic
gait, hypotonia, and cryptorchidism and other genital
malformations [3, 4]. Reports on recurrent infections are
ambiguous [3, 12]. Since PTHS individuals were found to
have low IgM levels and TCF4 targets several immuno-
globulin enhancer sites, it has been suggested that long-
term follow-up is needed to evaluate susceptibility to
infections, autoimmune disorders and tumours [10]. Indi-
viduals with PTHS typically show a smiling appearance,
but may also have an anxious or agitated disposition, and
they have frequently stereotypic movements [3, 4]. Based
on cross-sectional samples, two different systematics have
been suggested to help determining whether molecular
analysis of TCF4 is indicated and establishing a clinical
diagnosis (Table 1) [3, 13].
Longitudinal data on series of individuals with PTHS
are lacking. In general, the main factor hindering the
collection of data on the natural history of rare disorders
is formed by the small number of affected people within
individual countries and limited number of clinicians
and researchers working on each rare entity. But
patients and their families know the syndromes best.
Families are the continuous factor in the patients’ lives,
and know most about their development, behaviour and
health problems. This urges for the collection of longitu-
dinal information from large international groups within
a collaboration between clinicians, researchers and fam-
ilies. Thus, support groups should play a major role, as
typically they are organised internationally, have often
digitally communication structures and invariably are
very willing to contribute as gathering the information is
also a main goal for them [14].
We have recently built an internet database which al-
lows to gather longitudinal data on rare disorders, which
we called ‘waihonapedia’ (waihona [meaning treasure in
Hawaiian] encyclopaedia) [14]. The waihonapedias for
various rare disorders will offer unprecedented and
extremely valuable information on the natural history of
disorders. Prerequisites for a reliable waihonapedia are a
firm diagnosis, a secure database and guaranteed priv-
acy. Participants of each waihonapedia have their diag-
nosis confirmed by biochemical, metabolic or molecular
testing, or, if not possible, diagnoses are assessed by
medical advisors of support groups with outstanding ex-
perience in the disorder. Individuals with (ultra-)rare
disorders are easily recognisable, especially in combin-
ation with only limited personal data like age, gender
and country of origin, so safe data transmission is an
absolute prerequisite to guarantee privacy for partici-
pants and to obtain permission of both medical ethics
committees and patient groups to collect data.
Here we report on the information from the baseline
questionnaire of the PTHS waihonapedia. This includes
data on development, physical health and cognition, and
possible genotype-phenotype correlations of the first 101
individuals with PTHS in the waihonapedia database. In
addition we describe the results of evaluation of the two
classification systems of clinical diagnosis criteria within
part of the cohort.
Methods
Design
This is the cross-sectional baseline measurement of an
international long-term follow-up study into the natural
history of PTHS. The study has been approved by the
medical ethics committee of the Academic Medical
Centre in Amsterdam (W15_180#15.0217). The study
adheres to the Declaration of Helsinki for research
involving human subjects [15].
Participants
Participants were recruited through the Dutch and inter-
national Pitt-Hopkins Support Groups. Eligible for the
study were all individuals with a molecularly confirmed
diagnosis of PTHS. Support groups promoted the study
within their digital infrastructures (e.g. sites, social
media, newsletters), and contacted parents or caregivers
of eligible participants individually. As a result, parents/
caregivers emailed us to sign up for the questionnaire,
or, if the parents/caregivers consented, support groups
forwarded contact data to the research group. The re-
search group invited each family formally to the study,
with written information, and subsequently a personal
invitation was forwarded allowing the families to fill out
the online questionnaire.
Data collection
A questionnaire in lay language has been designed based
on published data on PTHS and general information
about basic development by 2 parents (JvH, SR), a
psychologist (MB), and a paediatrician-clinical geneticist
(RCMH). Subsequently, a pilot questionnaire was evalu-
ated for clarity and face validity by 5 families, which led
to somewhat adapted definitive questionnaire. It com-
prises 146 questions with main themes: general informa-
tion (date of birth, gender, country, weight, height, date
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of completion of the questionnaire), the diagnosis (exact
cause of PTHS, when and who diagnosed it), growth,
development (cognition, milestones, schooling, formal
testing), natural history (pregnancy, delivery, neonatal
period, feeding, toilet habits, sleeping, (unusual) move-
ments, epilepsy, problems with internal organs, infec-
tions), breathing patterns, appearance (face, hair, teeth,
skin, joints, hands, feet), sensory organs (vision, smell,
Table 1 Presence of Published Criteria Helping Establishing the Diagnosis in Present Cohort of PTHS individuals (items occurring
in > 75 % are indicated in bold)
Feature Marangi score Score cohort (%) Whalen score
Severe intellectual disability 2 47/47 (100%)
Absent speech (<5words) 2 32/47 (68 %) 2
Severe speech impairmenta 1 15/15 (100%)
Growth at birth normal 1 29/47 (62 %)
Overgrowth 1/47 (2 %) −1
Postnatal decrease of OFC 1 7/27 (26 %)
OFC < −3SD 0/47 (0 %) −2
Epilepsy/EEG abnormalities 1 17/47 (36 %)
Ataxia/motor incoordination 1 26/47 (55 %) 1
Walking >3 years/severe motor delay <3 years 44/47 (94%) 2
Hyperbreathing/apnoea 1 19/47 (40 %) 1
Constipation 1 40/47 (85%)
Abnormal brain MRIb 1 3/12 (25 %)
Eye anomalies 1c 25/47 (53 %)
Eye anomalies 21/47 (44 %) 1d
Typical PTHS facial featurese 4 24/47 (51 %)
Partial typical PTHS facial features 2 23/47 (49 %)
Deeply set eyes 23/41 (56 %) 1
Protrusion mid/lower face 36/47 (77%) 1
Broad nasal bridge or convex nasal ridgef 44/45 (98%) 1
High nasal bridgef 30/44 (68 %) 1
Flared nostrils 27/47 (57 %) 1
Large mouth 37/47 (79%) 1
Tented vermillion of upper lipf 20/47 (43 %) 1
Everted vermillion of lower lipf 37/46 (80%) 1
Visceral malformations 1/47 (2 %) −1
Stereotypy head/hands 22/47 (47 %) 2
Loss of purposeful hand skills 0/47 (0 %) −1
Hypotonia 27/47 (57 %) 1
Smiling appearance 24/47 (51 %) 1
Anxiety/agitation 16/47 (34 %) 1
Check for TCF4 mutation indicated If total score ≥10 29/47 (62 %)
3/42 (7 %) Patients ≥3 years:If total score ≥ 16
5/5 (100 %) Patients <3 years:If total score 10–15
Diagnostic If total score ≥13 4/47 (9 %) -
aMore than 10 words; 2–3 word sentences
bSmall callosal body; wide ventricles; thin hindbrain
cStrabismus, myopia, astigmatism
dStrabismus
eBitemporal narrowing, square forehead, deeply set eyes, hypotelorism, upslanted palpebral fissures, arched or thin eyebrows, broad nasal bridge, pointed nasal
tip, flaring nostrils, short philtrum, wide mouth, tented vermillion of upper lip, thick lower vermillionf
f Terminology changed to comply with international terminology “Elements of Morphology”
de Winter et al. Orphanet Journal of Rare Diseases  (2016) 11:37 Page 3 of 12
hearing), other diseases and admittance in hospital, and
any additional studies (electro-encephalography, brain
imaging). The questionnaire was available in English and
Dutch. Although not mandatory we invited families to
forward clinical pictures of the child with PTHS, to
allow for scoring of facial and limb characteristics by the
research group. Participants could fill out the question-
naire at once, but could also pause, as answers remain
stored, and continue at a later moment. Participants
could always correct previous answers until the answer-
ing was made definitive. The questionnaires themselves
were coded, with as single key a number that could be
linked to personal (contact) data. The key is stored in a
secure environment in the Academic Medical Centre in
Amsterdam. Data were collected between July 1, 2013
and July, 1 2015.
For the evaluation of the systems helping to diagnosis
PTHS clinically (Table 1) we used the clinical pictures
that were available of 47 participants. Two clinical genet-
icists with exceptional experience in PTHS (EKB;
RCMH) scored the PTHS participants independently
based on the information in the questionnaire and the
pictures.
Statistical analysis
Data were converted from the online questionnaire into
an anonymous SPSS file. Data were analysed using IBM
SPSS Statistics version 21.0 (Chicago, Il). Descriptive
statistics were used to provide information on preva-
lence and details on the various participant characteris-
tics. Chi-square analysis was performed to explore
genotype-phenotype correlations.
Results
Participants
We invited 139 families to participate. Of these, 101
families (72.7 %) completed the questionnaire. Families
indicated it took them 1 up to 5 hours to complete the
entire questionnaire. 54.5 % of the participating PTHS
individuals were men, the mean age was 9 years (median
age 8; range 0–32 years). Most participants came from
the USA (n = 36), the Netherlands (n = 17), and the UK
(n = 16) but also participants from 16 other countries
contacted the research group to sign up for the study.
The general data on participants and diagnosis are
shown in Table 2. Diagnostic processes differed, with
some receiving the diagnosis shortly after birth and
others years later, the oldest being 20 years when the
correct diagnosis was made.
Pregnancy, neonatal period, and development
Five people noted intra-uterine growth retardation and
two mentioned limited intra-uterine movements (Table 3).
Most parents first suspected that something was wrong
because milestones were not reached. Other signals picked
up as first signs by parents were failure to thrive, gastro-
intestinal problems (such as reflux, feeding problems,
vomiting, constipation), and other symptoms, such as
cyanosis during crying, breathing problems, seizures and
abnormal muscle tone. Some parents noted an unusual
facial appearance. Development was generally delayed.
Details about milestones are available in Table 4.
Physical health
Main physical health parameters are shown in Table 5.
Weight in relation to height, and height in relation to
age are shown in Figs. 1, 2, 3 and 4. The gradual devel-
opment with age of epilepsy is shown in Fig. 5. Of the
38 participants with epilepsy, 23.7 % became seizure free
at a mean age of 6.4 years. Most (51.4 %) had seizures
that included involuntary motor activity or tonic-clonic
seizures, often in combination with absences. 16.2 % had
absences only, for the remaining participants with epi-
lepsy, parents were not sure about the type of seizures.
An increase of the epilepsy was often noted during fever.
Overbreathing or apnoea’s shortly before a seizure were
also mentioned in 7 participants. 24 participants were
Table 2 Descriptives of the 101 Individuals with PTHS
Percent
Male 54.5
Female 45.5
Age 0–5 years 40.6
6–10 year 24.8
11–15 years 17.8
16–20 year 6.9
21–25 years 7.9
26–30 year 1.0
31–35 years 1.0
First suspicion something
was wrong
During pregnancy 3.1 %
Birth-6 months 56.3 %
>6 months-1 year 38.5 %
>1 year 2.1 %
Age at diagnosis Mean 7.1 year, range:
3 weeks–27 years
Cause of PTHS TCF4 deletion 41.1 %
TCF4 mutation 51.1 %
NRXN1 mutation 2.2 %
Parent not sure
but abnormality
present
5.6 %
Who made the diagnosis Geneticist 86.6 %
Paediatrician 7.2 %
Neurologist 5.2 %
Other 1.0 %
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on anti-epileptic drugs, with various anti-epileptics used,
mostly valproate, levetiracetam, lamitrigine and carba-
mazepine, or combinations of these. There was no spe-
cific medication that was more successful in decreasing
seizures than other medications. Seizures remained
therapy-resistant in some participants, but in most
therapy was successful. EEGs showed no epileptic
activity in 52.2 % of the cases (some were already on
anti-epileptic drugs or received sedative medication).
In all others epileptic activity was found. Lennox-
Gastaut syndrome was mentioned once. Neuro-
imaging was performed in 34 of the participants with
at least one epileptic seizure during their life, and
showed abnormalities in 2/3rd of them. Findings were
a small or absent callosal body (n = 4), an arachnoid
cyst which caused hydrocephaly and needed surgical
correction, another small arachnoid cyst without clin-
ical consequences, a hydrocephaly needing shunting,
and a diffuse reduction in white matter volume and
symmetric bilateral increase in T2 signal, involving
the globus pallidus.
The development of breathing anomalies in time is
shown in Fig. 6. Typically breathing anomalies increased
with time, but of the 34 PTHS individuals with breathing
anomalies 3 individuals subsequently stopped to have
breathing problems (mean age of stopping 4.3 years). In
one patient improvement of hyperbreathing pattern
coincided with cardiac surgery. Breathing anomalies
consisted usually of periods of rapid, sometimes irregular
breathing followed by breath holding. Sometimes this
cycle repeated itself several times one after another.
Rapid breathing episodes could be preceded by excite-
ment, stress or anxiety, but in others there was no ap-
parent reason and the participant remained comfortable
during both hyperbreathing and apnoea. Hyperbreathing
may lead to a swollen abdomen in 1/5thof the PTHS
individuals and a quarter turned pale with blue lips
during apnoea’s, some fainted. One participant had
obstructive sleep apnoea’s.
Gastrointestinal problems were common, especially
constipation (Table 5). Gastro-oesophageal reflux was
present in 37.6 % of the participants, and decreased with
age. Other gut problems were pyloric stenosis and mal-
rotation. Toothing and shedding of the milk teeth usu-
ally occurred at normal age. Other intra-oral problems
noted were ulcers (in 3 participants), fused teeth (in 3
participants), cleft lip and palate (once), a high palate
(once) and widely spaced teeth (twice). Open mouth
behaviour was mentioned in a few cases, but excessive
drooling was mentioned frequently (in 81 %).
Infectious disease included recurrent otitis, tonsil-
litis, frequent pneumonias, and once an endocarditis.
Immunological disturbances were reported twice: a
low IgA level and a low IgG level. There was one boy
with recurrent bladder infections. Genital problems
were a buried penis, small penis, vaginal aplasia
(which may have been accompanied by absent uterus
and ovaries, but this remains uncertain) and under-
developed internal genitalia.
Vision was frequently disturbed needing glasses, and
hearing was disturbed only infrequently (Table 5). In
addition to refraction errors, also strabismus, nystagmus,
astigmatism, disturbed depth vision and cortical visual
impairment occurred.
Behaviour
Behavioural characteristics are summarized in Table 6.
Behaviour during feeding includes gagging, choking and
not chewing properly. Some refuse food, or have very
strict rituals during feeding, but in general many are
described as excellent eaters. Sleeping patterns are
described in Table 6. Many parents mentioned that their
child sleeps excellently.
(Unusual) repetitive movements are described fre-
quently, such as head shaking, head banging, body
Table 3 Data on Pregnancy and Neonatal Period in 101 PTHS
individuals
Pregnancy Hypertension 10.5 %
Diabetes 3.1 %
Other 17.2 % (2x hypothyroidism,
1x low iron level,
7x infections, 1x
celiac disease, 1x
colitis ulcerosa, 2x
placenta praevia)
Delivery <37
weeks
9.6 %
Weight at birth Low birth
weight for
duration of
pregnancy
(<−2SD)
6.8 %
Mean birth
weight of
children born
at term
(pregnancy
≥ 37 weeks)
3173 g
Head circumference
at birth
Boys (n = 19) Mean 33.6 cm,
SD 1.6
Range 30–37.0 cm
Girls (n = 15) Mean 32.9 cm,
SD 2.6
Range 26–37.5 cm
Start Apgar score
at 1 min
≤6 8.4 %
7–10 68.7 %
Not sure 22.9 %
Apgar score
at 5 min
6 2.5 %
7–10 75.3 %
Not sure 22.2 %
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rocking and flapping, washing, clapping with arms
and hands. Flicking fingers is mentioned once. Hand
washing movements as in Rett syndrome are not un-
common, although clapping and flapping of the hands
occur mostly. Other unusual behaviour is rubbing the
toes together, hair pulling, temper tantrums, inappro-
priate laughing, hyperextending body or legs, and
throwing or banging or kicking on objects. Also
pinching, pressing and hitting oneself are mentioned.
Information on formal cognitive testing was available
from 21 participants. They were tested between 1.5 and
32 years of age (mean 8.8 years), and the range of devel-
opmental age was between 9 and 36 months (mean
14.5 months).
Genotype-phenotype correlations
No genotype-phenotype correlations were found for epi-
lepsy (chi-square = 4.98, p = .55) and breathing anomalies
(chi-square = 1.11, p = .98). This indicates that the preva-
lence of epilepsy and breathing anomalies was distributed
equally over the groups with a TCF4 deletion,TCF4 muta-
tion and NRXN1 mutation.
Comparison of diagnostic classification systems
The scoring of the individual facial signs was performed
by two of us (EB; RCMH), using the available clinical
pictures. The quality of the pictures was not always suffi-
cient to score all signs; if in doubt a sign was not scored.
The correlation of the two scorers for the specific signs
was good: they scored in total 678 signs of which they
concurred in 596 (88 %).
The total set of criteria defined by Whalen3 as suffi-
cient to indicate molecular analysis of TCF4 was met by
8 of the 47 PTHS individuals (17 %), and by the set of
criteria defined by Marangi4 indicated that 29 of the 47
PTHS individuals (62 %) should have been checked
molecularly. Marangi and co-authors indicated that a
score of 13 or higher was diagnostic for PTHS: this was
met by 4 of the present 47 individuals (9 %). As stated
above all participants of the present study had a molecu-
larly confirmed diagnosis of PTHS.
Table 4 Developmental Milestones per Age Category in 101 PTHS Individuals
Current skills Participants in age categories having acquired skill (age in years)
0–2 years
(n = 16)
3–5 years
(n = 22)
6–10 year
(n = 23)
11–15 years
(n = 16)
16–20 year
(n = 4)
21–25 years
(n = 8)
26 years +
(n = 2)
Laughing 86.7 % 100 % 100 % 100 % 100 % 85.7 % 100 %
Making noises 93.8 % 100 % 100 % 93.3 % 66.7 % 100 % 100 %
Keeping head up 87.5 % 95.2 % 100 % 93.3 % 100 % 100 % 100 %
Grasping objects 87.5 % 90.5 % 90.5 % 86.7 % 66.7 % 71.4 % 100 %
Turning from back to belly 81.3 % 90.5 % 90.5 % 86.7 % 100 % 85.7 % 100 %
Sitting unaided 56.3 % 90.9 % 95.5 % 100 % 100 % 85.7 % 100 %
Crawling 12.5 % 68.2 % 59.1 % 46.7 % 33.3 % 33.3 % 0.0 %
Standing unaided 12.5 % 28.6 % 77.3 % 73.3 % 66.7 % 71.4 % 100 %
Walking with aid 25.0 % 66.7 % 85.7 % 80.0 % 66.7 % 85.7 % 100 %
Walking unaided 6.3 % 31.8 % 76.2 % 78.6 % 33.3 % 71.4 % 100 %
Eating unaided 75.0 % 72.7 % 100 % 93.3 % 100 % 83.3 % 100 %
Eating with aid 31.3 % 50.0 % 57.1 % 37.5 % 66.7 % 57.1 % 100 %
Dressing unaided 0.0 % 0.0 % 4.8 % 0.0 % 0.0 % 14.3 % 0.0 %
Speaking single words 6.3 % 18.2 % 54.5 % 31.3 % 25.0 % 42.9 % 100 %
Speaking whole sentences 0.0 % 0.0 % 9.1 % 0.0 % 0.0 % 14.3 % 0.0 %
Potty trained urine 6.3 % 9.1 % 17.4 % 18.8 % 0.0 % 14.3 % 0.0 %
Potty trained poo 12.5 % 27.3 % 26.1 % 37.5 % 25.0 % 12.5 % 0.0 %
Previous and current problems
Feeding Problems Previously 31.3 % 50.0 % 22.7 % 37.5 % 0.0 % 28.6 % 50.0 %
Currently 31.3 % 4.5 % 4.5 % 0.0 % 0.0 % 0.0 % 0.0 %
Drinking problems Previously 6.3 % 22.7 % 27.3 % 12.5 % 0.0 % 12.5 % 0.0 %
Currently 31.3 % 13.6 % 18.2 % 12.5 % 0.0 % 25.0 % 0.0 %
Solid food problems Previously 6.3 % 22.7 % 13.6 % 37.5 % 0.0 % 14.3 % 0.0 %
Currently 37.5 % 31.8 % 13.6 % 31.3 % 25.0 % 0.0 % 0.0 %
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Table 5 Physical Health Problems in 101 PTHS Individuals
Age 0–2 years
(n = 16)
3–5 years
(n = 22)
6–10 year
(n = 23)
11–15 years
(n = 16)
16–20 year
(n = 4)
21–25 years
(n = 8)
26 years +
(n = 2)
Epilepsy
History of seizures 31.3 % 18.2 % 17.4 % 62.5 % 0 % 62.5 % 50.0 %
Currently seizures (out of
those with a positive history)
16.7 % 100 % 44.4 % 45.5 % 0 % 60.0 % 50.0 %
Breathing
History of breathing anomalies 20.0 % 22.7 % 21.7 % 68.8 % 100 % 50.0 % 100 %
Currently breathing anomalies
(out of those with a positive
history)
50.0 % 80.0 % 50.0 % 70.0 % 100 % 75.0 % 100 %
Gastrointestinal problems
Gastro-oesophageal reflux 56.3 % 42.9 % 33.3 % 28.6 % 25.0 % 14.3 % 50.0 %
Constipation 73.3 % 81.0 % 86.4 % 86.7 % 66.7 % 62.5 % 100 %
All ages
(Excessive) burping 28.7 %
Other gut problems 2.4 %
Vision
Near-sighted 31.7 %
Far sighted 21.7 %
Strabismus 44.7 %
Nystagmus 19.0 %
Tear duct blockage 11.8 %
Hearing
Examined 97.7 %
Impaired 10.3 %
Ability to smell
Hypersensitive to smell 2.4 %
(Seemingly) inability to smell 1.2 %
Mouth/tooth
Caries 8.3 %
Excessive drooling 81.4 %
Other intra-oral problems 41.2 %
Urogenital problems
Retractile testicles (n = 48) 6.3 %
Uni-/bilateral cryptorchidism 33.3 %
Surgical correction cryptorchidism 50.0 %
Other urogenital problems 17.4 %
Muscles/joints
Hypotonia 75.9 %
Hypertonia 6.9 %
Dislocated joints 1.1 %
Limited mobility fingers/wrists 27.9 %
Infections
Frequent recurrent infections 35.2 %
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Discussion
We have initiated a project which should lead to careful,
extensive data of a large series of individuals with PTHS
and several other genetically determined disorders creat-
ing and using the web-based questionnaire system
waihonapedia. The present report is the first report of
the series of PTHS individuals, describing the cross-
sectional data obtained at starting the project. Follow-up
as part of the waihonapedia system will allow to follow
the present individuals in time and obtain better insight
in the natural history. We aim at expanding the number
of PTHS participants as our aim is to follow a cohort of at
least 250 individuals. Furthermore the data on individuals
with various entities in which we are using or will use the
waihonapedia system (PTHS; Cornelia de Lange syn-
drome; Rubinstein-Taybi syndrome; Marshall-Smith
syndrome; Beckwith-Wiedemann syndrome; Nicolaides-
Baraitser syndrome; tuberous sclerosis; rare chromosome
anomalies and likely several others) will also allow com-
parison of data across syndromes, which will allow to
determine symptoms and complications that are truly typ-
ical for each syndrome. The waihonapedia system is safe,
Fig. 1 Boys length/height according to age
Fig. 2 Boys weight according to length/height
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has arrangements to secure privacy of participants, and is
fully automated and cheap [14], which are all prerequisites
for success.
The major characteristics on development, health
and behaviour of a relatively large cohort of PTHS in-
dividuals is provided here in Tables 2, 3, 4, 5 and 6.
We confirmed that the primary features of PTHS of
the total group of participants are intellectual disabil-
ity (100 %), epilepsy (32 %) and respiratory anomalies
(38 %). In most cases overbreathing increased with
age, but in a few cases it diminished over time. There
was no statistically significant genotype-phenotype
correlation for epilepsy and breathing anomalies, simi-
lar to what has been reported before [3]. Reflux
(38 %) and constipation (80 %) are also common in
the total group.
As a sub-study we combined the data from the present
questionnaire with evaluation of the facial morphology
of those participants that uploaded pictures (half of the
present cohort), to evaluate whether the two sets of cri-
teria that are used in practice [3, 13], yielded different
results. The results indicated that in general scoring of
facial signs by scorers experienced in a particular entity
using pictures submitted by families, shows a highly reli-
able correlation (scoring 88 % in agreement). The set of
criteria as defined by Marangi and co-workers4 to be
sufficient to establish a clinical diagnosis was met in
8.5 %. A score sufficient to warrant molecular studies
of TCF4 was met by 62 % (Marangi criteria) or 17 %
(Whalen criteria), although a molecularly confirmed
diagnosis was present in all participants. The Whalen
criteria contained several items which decreased the
Fig. 3 Girls length/height according to age
Fig. 4 Girls weight according to length/height
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score if present, such as overgrowth, visceral malfor-
mations and the loss of purposeful hand skills. Likely
this was added to discern PTHS from other, similar
entities such as Rett syndrome. Although useful in
clinical practise such signs or symptoms will be
hardly present and will decrease the score markedly.
In our opinion it is not useful to add such items in a
set of criteria: positively scoring items, especially
those that are not frequently found in related entities,
will be the most valuable. The facial signs as used by
Whalen and co-authors scored the characteristics in
the present cohort better than the facial signs as
mentioned by Marangi and co-authors: the typical
PTHS facial features, defined as the presence of more
than 50 % of the facial signs mentioned in the criteria
was present in 32/47 using the Whalen score and 24/
47 using the Marangi score.
While evaluating this relatively large number of PTHS
individuals in a short time both present scorers inde-
pendently noticed that there was often an asymmetry in
Fig. 5 Cumulative number of individuals with Pitt-Hopkins syndrome who developed epilepsy according to age
Fig. 6 Cumulative number of individuals with Pitt-Hopkins syndrome who developed breathing anomalies according to age
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the upslant of the palpebral fissures and indeed of the
upper 1/3rd of the face in general (present in 11/47). In
addition both noticed that the medial 2/3rd of the eye-
brows can be broad but it is especially the lateral 1/3rd
that is narrow and pencilled. We conclude that the
present sets of systematics helping in determining in
whom to evaluate the presence of an TCF4 mutation
may be helpful but are not yet sufficiently precise to be
used as diagnostic criteria. Well-functioning, inter-
nationally accepted criteria are therefore missing, while
these are mandatory for optimal diagnostics and man-
agement, and such initiative is urgently needed.
One may argue that diagnostic criteria are no longer
useful or needed as targeted whole exome or whole gen-
ome sequencing will rapidly be used as a first diagnostic
tool in individuals with intellectual disability. However,
the increasing yield of mutations in genes in individuals
who do not resemble the entity/entities known to be
caused by these genes, will ask for a more detailed evalu-
ation of the phenotype in order to assess causality of the
variant. Therefore detailed phenotyping is more needed
than ever [16].
Strengths of the present study are the relative large
number of participants for a rare entity as PTHS, all
diagnosed participants that were recruited through
support groups, which led to a high rate of participa-
tion, the careful and secure way data are gathered
and stored [14], building of the questionnaire with
help of the patient support groups, physicians and
social scientists, and the automated, cheap system of data
gathering which facilitates long-term data gathering.
Weaknesses of the present study are that we relied
on data from questionnaires, and did not perform a
standardized physical assessment of participants our-
selves, which is also a weakness as compared to other
studies. With (ultra-)rare disorders in which in a
single country the number of affected individuals is
small, personal investigation of individuals is impos-
sible for practical and financial reasons [16]. For
several participants questions had a (markedly) retro-
spective character, which may have caused a recall
bias. We will continue to include affected individuals
in the future, in whom such recall bias is not present,
which should allow us to compare answers by parents
of young and older participants, and to determine
whether this truly is a problem. Moreover clinical
items may be expected to be easier to answer for par-
ents than questions on electrophysiology or imaging.
Still, families turn out to be well aware of results of
studies performed in their child. We are planning to
ask permission of participants to collect for instance
the neuroimaging studies during follow-up.
There may also be an inclusion bias. We have no in-
formation about non-participating affected individuals.
One may expect that parents with higher educational
levels or those who are more active within support
groups, are more likely to participate. This potential bias
is present in many similar studies. We try to overcome
this by making access to the study and filling out the
questionnaire as simple as possible, and by including
more participants with time. Furthermore we are work-
ing on translating the questionnaire in multiple other
languages, allowing families to fill out a questionnaire
using their mother tongue.
At follow-up we will add several standardised be-
haviour checklists to the waihonapedia system. We
have gathered a series of 8 questionnaires, all vali-
dated and normalized, and which are at the present
being translated in the same large number of lan-
guages as the physical questionnaire, in a scientific-
ally acceptable manner. The repetitive follow-up will
allow yielding valuable information on natural history
of physical characteristics and behaviour of individ-
uals with PTHS. This information can potentially
also be used as historical normal values if interven-
tions are planned.
Table 6 Behavioural Characteristics in 101 PTHS Individuals
Behaviour Percent
Unusual behaviour during feeding 40.4 %
Sleep problems No longer periods
of sleep/frequently
awake at night
4.4 %
Other sleep problems 4.4 %
Problems falling asleep Previously 12.1 %
Currently 17.6 %
Problems sleeping the
whole night through
Previously 13.6 %
Currently 33.0 %
Night terrors Previously 6.6 %
Currently 5.5 %
Hand biting Previously 11.4 %
Currently 58.0 %
Mean age of start 4.2 years (range
0–23 years)
Teeth grinding Previously 28.9 %
Currently 46.7 %
Mean age of start 2.8 years (range
0–12 years)
Clapping/flashing/hand
washing
Previously 9.0 %
Currently 80.9 %
Mean age of start 1.7 years (range
0–15 years)
Repetitive movements Previously 4.4 %
Currently 66.7 %
Mean age of start 3.3 years (range
0.2–12 years)
de Winter et al. Orphanet Journal of Rare Diseases  (2016) 11:37 Page 11 of 12
Conclusion
The web-based questionnaire system waihonapedia is an
effective way to collect data on larger cohorts of people
with rare diseases globally as it secures privacy, is fully
automated and cheap. The first included cohort of 101
people with Pitt-Hopkins syndrome gives valuable infor-
mation on health, behaviour and development. The
number of participants will be expanded and there will
be a repetitive follow-up. The total project should lead
to better care of individuals with PTHS and similar
disorders.
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